Consensus Bruker Corporation

Stocks

BRKR

US1167941087

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			5-day change	1st Jan Change
60.06 ^USD	-0.86%		-2.56%	+27.49%

06-08	Bruker Corporation Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 11:40 AM
06-04	Bruker Corporation Showcases Expanding Microbiology and Infection Diagnostics Portfolio at ASM Microbe 2026	CI

Evolution of the Average Target: Bruker Corporation

Evolution of the Target Price: Bruker Corporation

Changes in Analyst Recommendations: Bruker Corporation

f05c97f4ef5e40b3a924f.9Da9u3IhiVtHWTyadl1Syk3ODqUvpZb21C-cXHoiDBI.hnDq6RlgwhwqK3rcMAVhsCidQvAf6MGTmXX6GhFzTneDZPCPE2--AR8vCA~aa45679c9a84c6293edabab2c48f01fd

Analysts' recommendations: Bruker Corporation

06-02	BofA Securities Adjusts Bruker Price Target to $65 From $49	MT
06-01	Analyst recommendations: Caesars Entertainment, Dell Technologies, AMD, Dycom Industries…
05-07	UBS Adjusts Price Target on Bruker to $45 From $40, Maintains Neutral Rating	MT
02-13	UBS Adjusts Price Target on Bruker to $40 From $43, Maintains Neutral Rating	MT
12-10	Wolfe Research Upgrades Bruker to Outperform From Peer Perform, $60 Price Target	MT
11-20	Rothschild & Co Redburn Initiates Coverage on Bruker With Buy Rating, $60 Price Target	MT
11-04	UBS Adjusts Price Target on Bruker to $43 From $40, Maintains Neutral Rating	MT
11-04	Analysts recommendations: Apple, Comcast, Crocs, Eli Lilly, Palantir…
11-03	(BRKR) Bruker Expects 2025 Non-GAAP EPS Range $1.85 to $1.90, vs. FactSet Est of $1.93	MT
11-03	Certain Restricted Stock Units of Bruker Corporation are subject to a Lock-Up Agreement Ending on 3-NOV-2025.	CI
22/05/25	Citigroup Downgrades Bruker to Neutral From Buy, Lowers Price Target to $40 From $50	MT
08/05/25	UBS Cuts Price Target on Bruker to $45 From $57, Keeps Neutral Rating	MT
14/04/25	BofA Securities Lowers Bruker Price Target to $61 From $76	MT
14/02/25	The glass is always half full
14/02/25	Analyst recommendations: Bunzl, Bellway, Shell, Coinbase, Spotify…
14/02/25	Analyst recommendations: Airbnb, Datadog, Avis, Coinbase, Roku...
19/12/24	Guggenheim Initiates Coverage on Bruker With Buy Rating, $72 Price Target	MT
10/12/24	UBS Downgrades Bruker to Neutral From Buy, Cuts Price Target to $66 From $102	MT
05/12/24	Goldman Sachs Upgrades Bruker to Neutral From Sell, Price Target is $60	MT
30/09/24	Wolfe Research Downgrades Bruker to Peer Perform From Outperform	MT
09/07/24	Goldman Sachs Adjusts Price Target on Bruker to $60 From $72, Maintains Sell Rating	MT
20/05/24	Stifel Adjusts Price Target on Bruker to $77 From $81, Maintains Hold Rating	MT
10/04/24	Goldman Sachs Raises Price Target on Bruker to $74 From $66, Maintains Sell Rating	MT
01/03/24	UBS Raises Bruker Price Target to $102 From $94, Maintains Buy Rating	MT
15/02/24	UBS Adjusts Bruker Price Target to $94 From $86, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BRUKER CORPORATION					-6.76%
	THERMO FISHER SCIENTIFIC, INC.					+12.09%
	INTUITIVE SURGICAL, INC.					+38.12%
	DANAHER CORPORATION					+21.71%
	BOSTON SCIENTIFIC CORPORATION					+64.98%
	EDWARDS LIFESCIENCES CORPORATION					+6.2%
	SIEMENS HEALTHINEERS AG					+33.42%
	AGILENT TECHNOLOGIES, INC.					+18.56%
	WATERS CORPORATION					+8.15%
	GE HEALTHCARE TECHNOLOGIES INC.					+22.02%
	Average					+21.85%
	Weighted average by Cap.					+24.59%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

60.06USD

Average target price

56.00USD

Spread / Average Target

-6.76%

High Price Target

70.00USD

Spread / Highest target

+16.55%

Low Price Target

35.00USD

Spread / Lowest Target

-41.72%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
UBS
Wolfe Research
Rothschild & Co Redburn
Citigroup
Guggenheim
Goldman Sachs
Stifel Nicolaus
JPMorgan Chase
Jefferies & Co.
Leerink Partners
TD Cowen
SVB Leerink
Wells Fargo Securities
Cleveland Research